Jump to ContentJump to Main Navigation
Show Summary Details

Reviews in the Neurosciences

Editor-in-Chief: Huston, Joseph P.

Editorial Board Member: Topic, Bianca / Adeli, Hojjat / Buzsaki, Gyorgy / Crawley, Jacqueline / Crow, Tim / Eichenbaum, Howard / Gold, Paul / Holsboer, Florian / Korth, Carsten / Lubec, Gert / McEwen, Bruce / Pan, Weihong / Pletnikov, Mikhail / Robbins, Trevor / Schnitzler, Alfons / Stevens, Charles / Steward, Oswald / Trojanowski, John


IMPACT FACTOR 2015: 3.198
5-year IMPACT FACTOR: 3.546
Rank 97 out of 256 in category Neurosciences in the 2015 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 1.605
Source Normalized Impact per Paper (SNIP) 2015: 0.912
Impact per Publication (IPP) 2015: 3.325

99,00 € / $149.00 / £75.00*

Online
ISSN
2191-0200
See all formats and pricing

 


Select Volume and Issue
Loading journal volume and issue information...

GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

Chong Gao1 / Christian Hölscher2 / Yueze Liu1 / 1

1Department of Physiology, Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, 030001, China

2School of Biomedical Sciences, University of Ulster, Coleraine, BT52 1SA, UK

Corresponding author

Citation Information: Reviews in the Neurosciences. Volume 23, Issue 1, Pages 1–11, ISSN (Online) 2191-0200, ISSN (Print) 0334-1763, DOI: 10.1515/rns.2011.061, December 2011

Publication History

Received:
2011-09-14
Accepted:
2011-12-21
Published Online:
2011-12-21

Abstract

As a constitutively active kinase, glycogen synthase kinase 3 (GSK3) is a kinase which regulates body metabolism by phosphorylation of glycogen synthase (GS) and other substrates. Considerable evidence suggests that GSK3 is involved in the common pathology underlying Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM). The overexpression or overactivation of GSK3 could induce a series of pathological changes, most of which are hallmarks of AD and T2DM. Therefore, GSK3 could be a novel target to treat these two age-dependent diseases. The inhibition of this kinase can prevent the aggregation of β-amyloid (Aβ) and hyperphosphorylation of tau protein. GSK3 inhibition can also be a promising strategy to ameliorate neurodegenerative developments. Its potential association with memory formation has been shown in electrophysiological and behavioral experiments. The neuroprotective effects of novel drugs developed to treat T2DM, glucagon-like peptide 1 (GLP-1) and its long-lasting analogs, have a possible link to GSK3 modification. Recent investigations of the interaction between the phosphatidylinositol 3 kinase (PI3K) signaling pathway and the protective effect of novel GPL-1 receptor agonist geniposide on PC12 cells support this theory.

Keywords: Alzheimer’s disease; β-amyloid (Aβ); glucagon-like peptide 1 (GLP-1); glycogen synthase kinase 3 (GSK3); neurofibrillary tangles (NFTs); type 2 diabetes mellitus (T2DM)

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Hsin-Hua Li, Shi-Lung Lin, Chien-Ning Huang, Fung-Jou Lu, Pai-Yi Chiu, Wen-Nung Huang, Te-Jen Lai, and Chih-Li Lin
Journal of Alzheimer's Disease, 2016, Volume 50, Number 4, Page 1083
[2]
Ramesh Kandimalla and P. Hemachandra Reddy
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2016, Volume 1862, Number 4, Page 814
[3]
Marwa A. Aziz, Rabah A.T. Serya, Deena S. Lasheen, and Khaled A.M. Abouzid
Future Journal of Pharmaceutical Sciences, 2016
[4]
Zhenzhen Liu, Tao Li, Ping Li, Nannan Wei, Zhiquan Zhao, Huimin Liang, Xinying Ji, Wenwu Chen, Mengzhou Xue, and Jianshe Wei
Oxidative Medicine and Cellular Longevity, 2015, Volume 2015, Page 1
[5]
Robert Linke, Ralph Pries, Michael Könnecke, Karl-Ludwig Bruchhage, Robert Böscke, Maximilian Gebhard, and Barbara Wollenberg
Annals of Allergy, Asthma & Immunology, 2013, Volume 110, Number 2, Page 101
[6]
Edna Grünblatt, Jasmin Bartl, Diana-Iulia Iuhos, Ana Knezovic, Vladimir Trkulja, Peter Riederer, Susanne Walitza, and Melita Salkovic-Petrisic
Journal of Molecular Psychiatry, 2015, Volume 3, Number 1
[7]
Prasanna Sivaprakasam, Xiaojun Han, Rita L. Civiello, Swanee Jacutin-Porte, Kevin Kish, Matt Pokross, Hal A. Lewis, Nazia Ahmed, Nicolas Szapiel, John A. Newitt, Eric T. Baldwin, Hong Xiao, Carol M. Krause, Hyunsoo Park, Michelle Nophsker, Jonathan S. Lippy, Catherine R. Burton, David R. Langley, John E. Macor, and Gene M. Dubowchik
Bioorganic & Medicinal Chemistry Letters, 2015, Volume 25, Number 9, Page 1856
[8]
Yili Wu, Philip T. T. Ly, and Weihong Song
Molecular Neurobiology, 2014, Volume 50, Number 3, Page 1085
[9]
Amira Zarrouk, Anne Vejux, John Mackrill, Yvonne O’Callaghan, Mohamed Hammami, Nora O’Brien, and Gérard Lizard
Ageing Research Reviews, 2014, Volume 18, Page 148
[10]
Samantha L. Goggin, Kevin K. Caldwell, Lee Anna Cunningham, and Andrea M. Allan
Toxicology Reports, 2014, Volume 1, Page 544
[11]
Juvenal A. Ríos, Pedro Cisternas, Marco Arrese, Salesa Barja, and Nibaldo C. Inestrosa
Progress in Neurobiology, 2014, Volume 121, Page 125
[12]
Kazuhiko Namekata, Atsuko Kimura, Kazuto Kawamura, Chikako Harada, and Takayuki Harada
Progress in Retinal and Eye Research, 2014, Volume 43, Page 1
[13]
Tatiana V. Lipina and John C. Roder
Neuroscience & Biobehavioral Reviews, 2014, Volume 45, Page 271
[14]
Eunyoung Lee, Ji-Eun Eom, Hye-Lin Kim, Kyung Hye Baek, Kyu-Yeon Jun, Hwa-Jung Kim, Minyung Lee, Inhee Mook-Jung, and Youngjoo Kwon
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2013, Volume 1831, Number 4, Page 709
[15]
Tiago Silva, Joana Reis, José Teixeira, and Fernanda Borges
Ageing Research Reviews, 2014, Volume 15, Page 116
[16]
H.-Y. Cai, C. Hölscher, X.-H. Yue, S.-X. Zhang, X.-H. Wang, F. Qiao, W. Yang, and J.-S. Qi
Neuroscience, 2014, Volume 277, Page 6
[17]
[18]
Manuel Torres, Samantha L. Price, Maria A. Fiol-deRoque, Amaia Marcilla-Etxenike, Hasna Ahyayauch, Gwendolyn Barceló-Coblijn, Silvia Terés, Loukia Katsouri, Margarita Ordinas, David J. López, Maitane Ibarguren, Félix M. Goñi, Xavier Busquets, Javier Vitorica, Magdalena Sastre, and Pablo V. Escribá
Biochimica et Biophysica Acta (BBA) - Biomembranes, 2014, Volume 1838, Number 6, Page 1680
[20]
James A. McCubrey, Nicole M. Davis, Stephen L. Abrams, Giuseppe Montalto, Melchiorre Cervello, Jorg Basecke, Massimo Libra, Ferdinando Nicoletti, Lucio Cocco, Alberto M. Martelli, and Linda S. Steelman
Advances in Biological Regulation, 2014, Volume 54, Page 176
[22]
J A McCubrey, L S Steelman, F E Bertrand, N M Davis, S L Abrams, G Montalto, A B D'Assoro, M Libra, F Nicoletti, R Maestro, J Basecke, L Cocco, M Cervello, and A M Martelli
Leukemia, 2014, Volume 28, Number 1, Page 15
[23]
Marcos Emilio Frizzo
Medical Hypotheses, 2013, Volume 81, Number 3, Page 376
[24]
Jun Tang, Yijin Pei, and Guangji Zhou
Experimental Gerontology, 2013, Volume 48, Number 8, Page 744
[25]
Hongyan Li, Hyung Min Jeong, You Hee Choi, Sung Ho Lee, Hye Gwang Jeong, Tae Cheon Jeong, and Kwang Youl Lee
Biochemical and Biophysical Research Communications, 2013, Volume 434, Number 3, Page 653
[26]
Jim R. Fadel, Corinne G. Jolivalt, and Lawrence P. Reagan
Ageing Research Reviews, 2013, Volume 12, Number 3, Page 764
[27]
Yasuko Kitagishi, Mayumi Kobayashi, Kanae Kikuta, and Satoru Matsuda
Depression Research and Treatment, 2012, Volume 2012, Page 1
[28]
Chaoyun Li, Azadeh Ebrahimi, and Hermann Schluesener
Ageing Research Reviews, 2013, Volume 12, Number 1, Page 116

Comments (0)

Please log in or register to comment.